Actively Recruiting
Use of Angiogenic Factors in the Conservative Management of Gestational Hypertension. Prospective, Randomised, Controlled Study.
Led by Saint Thomas Hospital, Panama · Updated on 2025-08-26
150
Participants Needed
1
Research Sites
6 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Gestational hypertension is a common complication during pregnancy that can lead to serious health problems for both mother and baby. Researchers are studying how to use angiogenic factors, which are substances in the blood, to better decide the safest time to end a pregnancy when gestational hypertension is diagnosed. This study aims to improve current guidelines that recommend delivery at 37 weeks by considering these factors to balance risks and benefits for mother and newborn. The study compares two groups of pregnant women diagnosed with gestational hypertension who have angiogenic factor levels (sFlt-1/PIGF) at or below 33. One group will have weekly check-ups and plan delivery at 39 weeks, while the other group will follow the current recommendation with delivery scheduled at 37 weeks. This randomized, controlled trial evaluates whether using these blood markers can guide more personalized timing for delivery. Participants will be monitored from the time of randomization until delivery, with weekly evaluations based on their assigned group. Researchers will track if gestational hypertension progresses to preeclampsia and assess health outcomes for both mother and baby up to hospital discharge. The study will measure maternal and fetal complications and neonatal health shortly after birth, helping to determine the best management approach. The total study duration varies from 1 to 17 weeks depending on when delivery occurs.
CONDITIONS
Brief Title
Angiogenic Factors in the Conservative Management of Gestational Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women between 24 and 40 weeks of gestation
- Diagnosis of Gestational Hypertension based on ACOG criteria
- Index sFlt-1/PIGF equal or below 33
You will not qualify if you...
- Multiple gestation
- Maternal vasculitis
- Previous cesarean section (3 or more)
- Neurological conditions
- Chronic renal disease
- Purpura
- Heart disease
- Index sFlt-1/PIGF of 34 or more
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Between 1 and 17 weeks
Participants with gestational hypertension and angiogenic factors (sFlt-1/PIGF) below or equal to 33 are evaluated weekly until scheduled termination of pregnancy at 37 or 39 weeks depending on group assignment.
Weekly visits until delivery
Duration - Up to approximately 7 days for maternal and 3 days for neonatal morbidity
Participants are monitored for maternal and neonatal morbidity until hospital discharge after delivery.
Visits as part of routine hospital care until discharge
Trial Site Locations
Total: 1 location
1
Hospital Santo Tomas
Panama City, Provincia de Panamá, Panama, 0834-1439
Actively Recruiting
Research Team
O
Osvaldo Reyes, MD
G
Gerado Cardenas, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here